CytomX Therapeutics
CTMX
109 hedge funds and large institutions have $400M invested in CytomX Therapeutics in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 30 reducing their positions, and 22 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 30
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
4% less funds holding
Funds holding: 113 → 109 (-4)
3.6% less ownership
Funds ownership: 82.27% → 78.67% (-3.6%)
18% less capital inflows, than outflows
Capital inflows: $46.1M | Capital outflows: $56.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$7.8M |
| 2 |
BVF Inc
San Francisco,
California
|
+$7.08M |
| 3 |
Millennium Management
New York
|
+$4.04M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$3.46M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.55M |
| 3 |
Pictet Asset Management (UK)
London,
United Kingdom
|
-$6.57M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.78M |
| 5 |
First Manhattan
New York
|
-$3.46M |
CTMX Hedge Fund Activity: Q2 2019 in Review
109 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2019, worth a combined $400M — down 0.03% from $400M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CTMX and 20 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 42 added.
The largest buyer was Nuveen, opening a new position worth an estimated $7.8M. The largest seller was Great Point Partners, exiting entirely with an estimated $10.3M sold.
- 109 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2019, down from 113 in Q1 2019.
- Funds reported $400M of CytomX Therapeutics stock for Q2 2019, down 0.03% quarter-over-quarter.
- 20 funds opened new CytomX Therapeutics positions in Q2 2019 and 22 closed out, a net change of -2 holders.
- The largest CytomX Therapeutics buyer in Q2 2019 was Nuveen, an estimated $7.8M added.
- The largest CytomX Therapeutics seller in Q2 2019 was Great Point Partners, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2019.